CencoraCOR
Market Cap: $46.1B
About: Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Employees: 46,000
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
110% more call options, than puts
Call options by funds: $1.68B | Put options by funds: $803M
11% more repeat investments, than reductions
Existing positions increased: 440 | Existing positions reduced: 395
1.1% less ownership
Funds ownership: 99.85% [Q1] → 98.76% (-1.1%) [Q2]
3% less funds holding
Funds holding: 1,135 [Q1] → 1,102 (-33) [Q2]
8% less capital invested
Capital invested by funds: $48.3B [Q1] → $44.4B (-$3.9B) [Q2]
22% less funds holding in top 10
Funds holding in top 10: 23 [Q1] → 18 (-5) [Q2]
26% less first-time investments, than exits
New positions opened: 94 | Existing positions closed: 127
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Baird David Rodgers 88% 1-year accuracy 7 / 8 met price target | 20%upside $283 | Outperform Maintained | 6 Sept 2024 |
JP Morgan Lisa Gill 67% 1-year accuracy 16 / 24 met price target | 22%upside $287 | Overweight Maintained | 21 Aug 2024 |
Wells Fargo Stephen Baxter 59% 1-year accuracy 17 / 29 met price target | 6%upside $249 | Equal-Weight Maintained | 1 Aug 2024 |
Baird David Rodgers 88% 1-year accuracy 7 / 8 met price target | 22%upside $287 | Outperform Maintained | 1 Aug 2024 |
Baird David Rodgers 88% 1-year accuracy 7 / 8 met price target | 21%upside $285 | Outperform Maintained | 9 Jul 2024 |
Financial journalist opinion
Based on 9 articles about COR published over the past 30 days